Editorial

CAR T-Cell Therapy for Large B-Cell Lymphoma

Maritza C. Alencar, DNP, MBA, APRN-BC, BMTCN®

UM Sylvester Comprehensive Cancer Center, Miami, Florida

Author’s disclosures of conflicts of interest are found at the end of this article.

Maritza C. Alencar, DNP, MBA, APRN-BC, BMTCN®, UM Sylvester Comprehensive Cancer Center, 1400 NW 10th Avenue, #605, Miami, Florida 33136. E-mail: mcalencar@miami.edu


J Adv Pract Oncol 2019;10(suppl 3):5–9 | https://doi.org/10.6004/jadpro.2019.10.4.9 | © 2019 Harborside™


  

ABSTRACT

Abstract

Chimeric antigen receptor (CAR) T-cell therapy represents an exciting innovation in the treatment of cancer. With the approval of two revolutionary anti-CD19 CAR T-cell therapies (axicabtagene ciloleucel [Yescarta] and tisagenlecleucel [Kymriah]) for relapsed/refractory large B-cell lymphoma, health-care providers must consider how to prepare for the future of cancer care. While these therapies have been shown to provide clinical benefit to many patients, they are associated with a range of adverse events (AEs) that will need to be identified, assessed, and managed. Widespread education of health-care providers, patients, and caregivers will also be essential to ensure the success of this novel treatment. This supplement aims to provide practical information to the advanced practitioner on a number of considerations relating to the implementation and expansion of CAR T-cell therapy, including CAR T-cell biology and mechanism of action, how to identify, grade, and manage treatment-related AEs, as well as best practices for educating patients and caregivers about this type of therapy.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.